Walter Investment Management Corp. (WAC) Forms $0.65 Double Bottom; Stemline Therapeutics (STML)’s Sentiment Is 1.24

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics in the United States. The company has market cap of $459.21 million. The firm develops SL-401, a targeted therapy directed to the interleukin-3 receptor , which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It currently has negative earnings. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer.

Walter Investment Management Corp. (WAC) formed double bottom with $0.62 target or 5.00% below today’s $0.65 share price. Walter Investment Management Corp. (WAC) has $24.41 million valuation. The stock decreased 2.99% or $0.0201 during the last trading session, reaching $0.6531. About 567,751 shares traded. Walter Investment Management Corp. (NYSE:WAC) has declined 63.57% since February 2, 2017 and is downtrending. It has underperformed by 80.27% the S&P500.

Among 6 analysts covering Walter Investment Management Corp (NYSE:WAC), 0 have Buy rating, 3 Sell and 3 Hold. Therefore 0 are positive. Walter Investment Management Corp has $10 highest and $100 lowest target. $4.75’s average target is 627.30% above currents $0.6531 stock price. Walter Investment Management Corp had 10 analyst reports since September 1, 2015 according to SRatingsIntel. Keefe Bruyette & Woods upgraded Walter Investment Management Corp. (NYSE:WAC) on Monday, November 9 to “Market Perform” rating. The stock of Walter Investment Management Corp. (NYSE:WAC) earned “Hold” rating by Zacks on Tuesday, September 1. Keefe Bruyette & Woods maintained it with “Sell” rating and $100 target in Monday, May 29 report. Credit Suisse maintained Walter Investment Management Corp. (NYSE:WAC) rating on Monday, March 7. Credit Suisse has “Neutral” rating and $9 target. The rating was upgraded by Wells Fargo on Thursday, May 11 to “Market Perform”. The stock of Walter Investment Management Corp. (NYSE:WAC) earned “Hold” rating by Zacks on Tuesday, September 8. FBR Capital maintained the stock with “Underperform” rating in Friday, November 6 report. The stock has “Underperform” rating by Keefe Bruyette & Woods on Tuesday, December 13. The rating was maintained by Barclays Capital on Wednesday, August 10 with “Underweight”.

Investors sentiment decreased to 0.22 in Q3 2017. Its down 0.28, from 0.5 in 2017Q2. It turned negative, as 18 investors sold Walter Investment Management Corp. shares while 18 reduced holdings. 5 funds opened positions while 3 raised stakes. 14.39 million shares or 23.76% less from 18.87 million shares in 2017Q2 were reported. Federated Pa stated it has 0% of its portfolio in Walter Investment Management Corp. (NYSE:WAC). 626,353 are owned by Blackrock. Amer Gru reported 0% of its portfolio in Walter Investment Management Corp. (NYSE:WAC). 12,031 are owned by Morgan Stanley. Bank & Trust Of America De reported 201 shares. Geode Capital Management Ltd Liability Company has 0% invested in Walter Investment Management Corp. (NYSE:WAC). First Pacific Advsr Ltd Llc, a California-based fund reported 221,049 shares. Parametric Portfolio Assoc Ltd reported 0% stake. Panagora Asset Management Inc owns 0% invested in Walter Investment Management Corp. (NYSE:WAC) for 894 shares. Ameritas Investment Ptnrs invested in 0% or 3,297 shares. Edge Wealth Mngmt Ltd Liability Company, New York-based fund reported 66,940 shares. National Bank & Trust Of New York Mellon reported 0% of its portfolio in Walter Investment Management Corp. (NYSE:WAC). 1,603 were accumulated by Bnp Paribas Arbitrage Sa. Price T Rowe Associates Md reported 16,168 shares or 0% of all its holdings. Birch Run Capital Advsr Lp holds 1.56% of its portfolio in Walter Investment Management Corp. (NYSE:WAC) for 7.47 million shares.

The stock decreased 0.63% or $0.1 during the last trading session, reaching $15.85. About 209,331 shares traded. Stemline Therapeutics, Inc. (STML) has risen 52.65% since February 2, 2017 and is uptrending. It has outperformed by 35.95% the S&P500.

Since January 1, 0001, it had 0 buys, and 3 selling transactions for $422,597 activity.

Lyon Street Capital Llc holds 2.32% of its portfolio in Stemline Therapeutics, Inc. for 541,462 shares. Eventide Asset Management Llc owns 1.09 million shares or 0.68% of their US portfolio. Moreover, Sphera Funds Management Ltd. has 0.48% invested in the company for 300,000 shares. The New York-based Knott David M has invested 0.36% in the stock. Carl Domino Inc, a Florida-based fund reported 26,000 shares.